CLAIRIgene selected to present at AAIC. To view the poster click below

Jul 2023

https://alz.confex.com/alz/2023/meetingapp.cgi/Paper/80698

CLAIRIgene featured in MedicalNewsToday

Jul 2023

https://www.medicalnewstoday.com/amp/articles/could-crispr-gene-therapy-help-treat-alzheimers-disease

CLAIRIgene featured by STAT News

Jul 2023

Researchers turn to CRISPR to unlock one of the trickiest diseases to treat:...

CLAIRIgene’s Alzheimer’s program received its first STTR award from the National Institute on Aging of the National Institutes of Health for the project entitled, “APOE-targeted therapy for precision medicine in late onset Alzheimer’s disease: A novel epigenome editing approach for downregulation of APOEe4 expression”

Aug 2022

Dr. Kantor discussed CLAIRIgene’s APOE-targeted epigenome therapy for Alzheimer’s in an interview for VJDementia as part of the journal series for AAIC 2022. 

Aug 2022

Click at the link Developing APOE targeted epigenome therapy for the treatment of Alzheimers Disease to listen to the interview.

Dr. Chiba-Falek participated as a panelist in the Alzheimer’s Association Business Consortium (AABC) Panel at the AAIC 2022 for a discussion on Therapeutic targets & strategies in Alzheimer’s disease 

Jul 2022